The partnership between Sensible Biotechnologies and Ginkgo Bioworks aims to develop an in vivo alternative to in vitro mRNA manufacturing technology. The in vivo mRNA manufacturing method Sensible and Ginkgo are jointly developing is designed to scale to produce 100,000 L of product. The partnership has an overarching aim to manufacture better quality mRNA over traditional IVT. According to Sensible Biotechnologies, an early-stage biotechnology company based in Europe, and Ginkgo, which is building a platform for cell programming and biosecurity, the mRNA…

Thermo Fisher Scientific and Arsenal Biosciences said its updated partnership will further advance  the development of production processes for cancer treatments. Contract development manufacturing organization (CDMO) Thermo Fisher first teamed up with clinical-stage cell therapy firm manufacturing chimeric antigen receptor (CAR)-T cell therapies ArsenalBio in 2020. Under the terms of the deal, Thermo Fisher aimed to support ArsenalBio to tackle specific challenges connected with cell therapy production by working as a team to aid advancement of a clinical-scale gene editing…